Statement: The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal.
Primary_evidence: Outcome Measurement:    Progression-free Survival (PFS)   PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause.   Time frame: From date of randomization to discontinuation due to disease progression or death up to primary completion date (Median follow-up 6 months) Results 1:    Arm/Group Title: Exemestane 25 mg + Placebo   Arm/Group Description: Exemestane (Aromasin  ) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.   Overall Number of Participants Analyzed: 66   Median (95% Confidence Interval)   Unit of Measure: months  2.27        (1.81 to 3.68) Results 2:    Arm/Group Title: Exemestane 25 mg + Entinostat 5 mg   Arm/Group Description: Exemestane (Aromasin  ) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.   Overall Number of Participants Analyzed: 64   Median (95% Confidence Interval)   Unit of Measure: months  4.28        (3.26 to 5.36)